Evidence mapPaperPMID 37761102Full record

ReviewFoods (Basel, Switzerland)2023

Benefits of Combining

Wenwu Huang, Boyuan Shen, Xiumei Li, Tongcun Zhang, Xiang Zhou

Abstract readReview
In one paragraph

Review in Foods (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Frontiers in endocrinology · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenwu HuangCollege of Life Sciences & Health, Wuhan University of Science & Technology, Wuhan 430065, China.ORCID 0009-0001-6761-2314
Boyuan ShenCollege of Life Sciences & Health, Wuhan University of Science & Technology, Wuhan 430065, China.
Xiumei LiKey Laboratory of Feed Biotechnology, Ministry of Agriculture and Rural Affairs, Institute of Feed Research of CAAS, Beijing 100000, China.
Tongcun ZhangCollege of Life Sciences & Health, Wuhan University of Science & Technology, Wuhan 430065, China.
Xiang ZhouCollege of Life Sciences & Health, Wuhan University of Science & Technology, Wuhan 430065, China.

Funding

Ministry of Science and Technology of the People's Republic of China 2017YFD0400300
6 · The paper itself

Abstract

Non-alcoholic fatty liver disease, commonly abbreviated to NAFLD, is a pervasive ailment within the digestive system, exhibiting a rising prevalence, and impacting individuals at increasingly younger ages. Those afflicted by NAFLD face a heightened vulnerability to the onset of profound liver fibrosis, cardiovascular complications, and malignancies. Currently, NAFLD poses a significant threat to human health, and there is no approved therapeutic treatment for it. Recent studies have shown that synbiotics, which regulate intestinal microecology, can positively impact glucolipid metabolism, and improve NAFLD-related indicators.

Indexed as

gut microbiotaNAFLDSonchus brachyotus DC. extractssynbiotics

Identifiers

PMID37761102
PMCPMC10530047

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.